NCT04701151 2026-03-03
NORTH-REG Dwell-Time Study
Aarhus University Hospital
Phase 4 Active not recruiting
Clinical Trials
20 trialsNCT07064863 2025-07-17
BCG-TIME
Queen's University
Phase 1/2 Not yet recruiting
NCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
NCT06767982 2025-01-10
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
Ankara University
Phase 4 Completed
NCT03799835 2024-12-11
ALBAN
UNICANCER
Phase 3 Active not recruiting
NCT04806178 2024-12-09
IMMUNOBCG
University of Campinas, Brazil
Phase 3 Completed
NCT06187506 2024-07-12
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT02948543 2023-06-18
BCG+MM
University of Sydney
Phase 3 Unknown
NCT05701332 2023-01-27
Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume
Assiut University
Phase 4 Unknown
NCT00070070 2022-10-12
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT01838200 2022-10-12
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT01373294 2019-08-06
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03790384 2018-12-31
MITOBCG
Azienda Ospedaliera "Sant'Andrea"
Phase 4 Unknown
NCT02326168 2017-01-25
PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase EARLY_PHASE1 Completed
NCT00974818 2015-11-20
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 3 Terminated
NCT01498172 2015-02-04
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
University of Lausanne Hospitals
Phase 1 Completed
NCT00004122 2013-02-01
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00003023 2013-01-18
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01442519 2011-09-28
BCG/EMDA-MMC
University of Rome Tor Vergata
Phase 3 Completed
NCT00330707 2011-03-04
Combined Use of BCG and Interferon Alpha in Bladder Cancer
National University Hospital, Singapore
Phase 2/3 Completed